Legend Biotech (STU:9LB) Other Stockholders Equity: €170 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9LB Legend Biotech Corp STU:9LB
73 GF Score
Price €15.30
GF Value €70.51
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Legend Biotech Other Stockholders Equity?

Legend Biotech STU:9LB 73 Other Stockholders Equity is €170 Mil as of Jun. 2026. GuruFocus rates STU:9LB with a GF Score™ of 73/100 and a GF Value™ of €70.51 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Legend Biotech's Other Stockholders Equity for the quarter that ended in Jun. 2026 was €170 Mil.

Legend Biotech's quarterly Other Stockholders Equity declined from Dec. 2025 (€179 Mil) to Mar. 2026 (€173 Mil) and declined from Mar. 2026 (€173 Mil) to Jun. 2026 (€170 Mil).

Legend Biotech's annual Other Stockholders Equity declined from Dec. 2023 (€90 Mil) to Dec. 2024 (€6 Mil) but then increased from Dec. 2024 (€6 Mil) to Dec. 2025 (€179 Mil).

Legend Biotech Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Legend Biotech's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech Other Stockholders Equity Chart

Legend Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 21.60 50.33 89.55 6.05 178.98

Legend Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 882.14 170.75 178.98 173.15 169.86
STU:9LB
73GF Score
Legend Biotech Corp STU:9LB
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Legend Biotech Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €170 Mil mean?
Legend Biotech (STU:9LB) has a Other Stockholders Equity of €170 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Other Stockholders Equity too high?
Legend Biotech's current Other Stockholders Equity is €170 Mil. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Other Stockholders Equity compare to IDYA and DNLI?
Legend Biotech's Other Stockholders Equity of €170 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Legend Biotech and its competitors. Legend Biotech's current Other Stockholders Equity is €170 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (STU:9LB) is currently considered Significantly Undervalued. The stock's GF Value™ is €70.51, compared to a current price of €15.30 — trading 78.3% below its estimated fair value. The current Other Stockholders Equity is €170 Mil. Legend Biotech's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Legend Biotech (STU:9LB), the current Other Stockholders Equity is €170 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (STU:9LB) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of €15.30 is trading 78.3% below its estimated GF Value™ of €70.51. GuruFocus considers Legend Biotech to be Significantly Undervalued.

Key valuation signals for STU:9LB:

  • Other Stockholders Equity: €170 Mil
  • GF Value™: €70.51 vs. price of €15.30 (78.3% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the STU:9LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges LEGN:USA
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score

Get the complete analysis for STU:9LB

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.30
Price
€70.51
GF Value